Clinical Trial Update: Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and tolerability of nirsevimab in immunocompromised children has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rsv Infection

Drugs mentioned

• Nirsevimab (nirsevimab)

Snippet

Sponsor: AstraZeneca | Conditions: RSV Infection | Phase 2 | Status: COMPLETED | Results posted: 2023-11-15